GLP-1 Cost in 2026: $249/mo Telehealth Plans Compared

On August 28, 2026, DirectMeds announced expanded access to doctor-guided GLP-1 weight management programs starting at $249 per month, with no separate membership fees or hidden charges (GlobeNewswire, Aug 28, 2026). It is the latest data point in a year of aggressive telehealth price cuts — and a concrete anchor for how much GLP-1 actually costs in 2026. In short, the GLP-1 cost 2026 range runs from about $59–$99/month on the cheapest compounded telehealth plans (GLP1Picks, read September 20, 2026) to more than $1,349/month for brand-name Wegovy at list (GLP-1 Daily). Everything between depends on insurance, formulation, and channel — and the Fifth Circuit’s compounded GLP-1 ruling is about to make some of it less available.

Update — September 20, 2026. GLP-1 pricing queries are now contested mostly by vendor-owned comparison pages: our census of one seller’s batch counted 232 comparison pages published in six days, all under a single byline — the CEO of the company the page ranks first. This page is a per-provider price table, not a ranking, but it makes the same kind of dated claim those pages make, so it is held to the same test here. The method sentence now names the seven first-party rows and the two that are not, the Found and PlushCare rows carry that label in their own Caveats cell, the brand-list price and the percentage band are consistent across the body, the FAQ and the schema, and the cheapest-compounded floor is re-read as of today. For how to read any of these comparisons, including ours, see How to Tell If a GLP-1 Price Comparison Is Trustworthy.

What DirectMeds’ $249/Month GLP-1 Program Includes

The $249/month figure covers sublingual semaglutide. DirectMeds’ press release describes the price as all-inclusive: one monthly number that includes provider oversight, medication when approved, ongoing clinical support, and shipping, with “no separate membership fees or hidden charges” (GlobeNewswire, Aug 28, 2026). Injectable semaglutide or tirzepatide starts at $297/month in the same release, while the landing page lists injectable tirzepatide at $497/month (DirectMeds landing page).

The program is physician-guided and nationwide: DirectMeds says eligible adults across the United States get access to licensed U.S. healthcare providers via telehealth, with follow-up care and dosage adjustments through a secure portal (GlobeNewswire, Aug 28, 2026). How much vetting that model involves varies by seller — GLP-1 Telehealth: Fewer Than a Third Consult a Doctor counted how many of these programs require a real-time consultation before a prescription is written. Payments are HSA/FSA-eligible, there is a free eligibility assessment, and prescriptions are filled through licensed U.S. pharmacies and shipped in temperature-controlled packaging. Two caveats: pricing is “starting at,” and medication is prescribed only when clinically appropriate — not every applicant qualifies (GlobeNewswire, Aug 28, 2026). The service is not available in Mississippi (DirectMeds).

One point worth flagging: the release does not state whether its sublingual semaglutide is an FDA-approved product or a compounded formulation (GlobeNewswire, Aug 28, 2026) — and sublingual is not an FDA-approved semaglutide dosage form. DirectMeds’ landing page describes the offering as compounded under 503A rules, not FDA-approved, and the company is LegitScript-certified (DirectMeds landing page). Third-party coverage corroborates the tier structure — sublingual at $249/month, injectable at $297/month — and puts the tirzepatide price per month near $397 (SeekPeptides).

How Much Does GLP-1 Cost in 2026?

The honest answer is a range, not a price: brand-name list prices sit at roughly $1,028–$1,349/month for Ozempic and Wegovy, about $1,086 for Zepbound, and about $649 for Lilly’s oral Foundayo (RX Index, GLP-1 US). But most people don’t pay list. Manufacturer cash-pay programs price the Wegovy pill at $149–$199/month, Wegovy injectables from $199/month intro pricing rising to $349, Zepbound vials at $299–$449, and Foundayo at $149–$349 (GLP-1 Daily, RX Index).

Three other channels matter in 2026. With insurance plus a manufacturer savings card, out-of-pocket costs can fall to $25 or less (GLP-1 Daily). The Medicare GLP-1 Bridge program, which started July 1, 2026 and runs through December 31, 2027, gives eligible Part D members access to covered brand-name GLP-1s for about $50/month (CMS). And compounded semaglutide via telehealth — the channel DirectMeds’ new price sits in — runs roughly $99–$397/month depending on provider and formulation (RX Index, GLP-1 US). When a plan won’t pay at all, the GLP-1 cost without insurance can run from $129 to $1,865 per month depending on channel. The same price pressure that pushed telehealth brands to pivot into peptides keeps driving these numbers down. For the newest Health Canada authorization of a generic semaglutide — Sandoz’s, in September 2026 — and what it does and does not change about price, see our Canadian generic semaglutide explainer.

Employer Coverage: Why Many Plans Still Won’t Pay for GLP-1s

Whether your GLP-1 is covered often comes down to your employer’s health plan — and many employers still don’t cover weight-loss GLP-1s. In a June 2026 survey of more than 31,000 employer organizations, only 36% covered GLP-1s for both diabetes and weight loss, 60% covered them for diabetes only, and 3% didn’t cover them at all (Becker’s Payer Issues / IFEBP, Jul 7, 2026). KFF’s Employer Health Benefits Survey shows a similar picture: the share of employers offering obesity-drug coverage barely moved from 18% in 2024 to 19% in 2025, while the share not offering it rose from 52% to 57% (NPR, Apr 22, 2026).

Some employers have gone from declining to cover to cutting back. ABC News reported on August 29, 2026 that Cigna stopped covering GLP-1s for weight loss in its own employee health plan on July 1, 2026, and PepsiCo cut GLP-1 weight-loss coverage due to rising costs while continuing to cover the drugs for employees who use them for diabetes (ABC News, Aug 29, 2026). For patients who lose coverage, the result can be steep: “The drugs can sometimes cost more than $1,000 per month out of pocket” (ABC News, Aug 29, 2026). We break down why employers keep saying no — and what to do when a plan stops paying — in our explainer on the employer GLP-1 coverage gap.

The coverage gap is one reason the market is shifting. Oral GLP-1s now give patients a lower-cost brand-name option — the Wegovy pill at $149–$199/month and Lilly’s Foundayo at $149–$349/month (GLP-1 Daily) — and compounded telehealth plans have been the budget tier, though the Fifth Circuit’s compounded GLP-1 ruling is tightening what compounders can legally offer.

Medicare GLP-1 Bridge: $50/Month Wegovy, Zepbound, or Foundayo

If you are on Medicare, the cheapest covered path may not be a telehealth plan at all. The Medicare GLP-1 Bridge — a CMS demonstration running July 1, 2026 through December 31, 2027 — gives qualifying Part D beneficiaries Wegovy, Zepbound, or Foundayo for about $50/month, flat regardless of income (CMS, Medicare.gov). The covered forms are narrower than the retail market: Wegovy (semaglutide) injection or tablet, Zepbound (tirzepatide) in the KwikPen only, and oral Foundayo (orforglipron) tablet — the Zepbound single-dose pen and vials, plus Ozempic, Mounjaro, Rybelsus, and Trulicity, are not covered (CMS). Eligibility requires Part D coverage, no existing GLP-1 through your drug plan, and the program’s age and BMI thresholds — and you don’t enroll in the Bridge; a prescriber starts it. Our Medicare GLP-1 Bridge explainer covers who qualifies and how the $50/month process works.

GLP-1 Telehealth Pricing Compared: 9 Providers

Every price below is a “starting at” figure. Seven of the nine rows were read from the provider’s own pricing page on August 29, 2026; the Found and PlushCare rows are third-party figures from a page last updated July 17, 2026 and are labelled as such below. Almost every provider splits the bill into a membership or program fee plus medication — compare the total, not the headline. DirectMeds’ all-inclusive $249/month sublingual tier undercuts the membership-plus-meds bundles on paper (GlobeNewswire, Aug 28, 2026), though its release only discloses “starting at” pricing.

Provider	Starting price (observed Aug 29, 2026 unless noted)	What’s included	Caveats
DirectMeds	$249/mo sublingual semaglutide; $297/mo injectable (PR, landing)	All-in: medication, doctor visits, clinical support, shipping; no membership fee	“Starting at”; prescription only if clinically appropriate; not available in MS
Hims	Meds from $149/mo (pills), $199/mo (pens), $299/mo (Zepbound) (Hims)	Membership ($39 first mo, then $149/mo) + branded meds billed separately	Total = membership + meds; no compounded options listed
Ro	Membership $39 first mo, then $74/mo prepaid annual (Ro)	Provider support, coaching, insurance concierge, lab testing; meds extra	Branded GLP-1s ~$900–1,000/mo cash on top (Everyday Health)
Noom Med	$129 start, then $249/mo (Rx tier); Microdose from $49 start (Noom)	All-in: clinical care, medication, digital program	Quarterly billing; all-inclusive tiers are compounded
Mochi Health	Membership $39 first mo, then $79/mo; meds from $60/mo (Mochi)	Unlimited physician + care team, coaching; meds separate	Compounded availability varies by state and is legally constrained post-ruling
WeightWatchers	Med+ $25 first mo, then $74/mo (12-mo plan) (WW)	Clinical care, insurance/affordability support, program	Meds NOT included; 12-month auto-renew commitment
Found	$2,388 up front / 6-mo with insurance; $3,588 without (Everyday Health)	Physician-led care team, coaching; meds extra	Third-party price (Everyday Health, updated July 17, 2026), not read from Found’s own page; 6-month commitment + $129 cancellation fee
LifeMD	Program & provider fee $149/mo (first mo $39) + Wegovy from $149 (pill) / $199 (pen) (LifeMD)	Clinical care, coaching, lab work; meds extra	Nonrefundable membership
PlushCare	$19.99/mo membership + $129/visit without insurance (Everyday Health)	Doctor visits and refills; no structured program	Third-party price (Everyday Health, updated July 17, 2026), not read from PlushCare’s own page; bloodwork required; pharmacy cost varies with insurance

Other cash-pay options in the same market: Sesame charges $99/month plus medication cost; Walgreens Weight Management charges $49 per appointment with medication from $149/month; GoodRx’s unlimited online care runs $119/month plus medication (Everyday Health, updated Jul 17, 2026).

Is $249/Month a Good Price for Semaglutide?

The short answer to the semaglutide price per month question is yes — with the positioning right. Against brand-name semaglutide list prices of roughly $1,028–$1,349/month, $249/month all-in is about 76–82% less, and the single price includes medication, doctor visits, shipping, and supplies with no membership fee (RX Index, DirectMeds landing page). But it is not the market floor: the compounded semaglutide cost starts around $99/month, and GLP1Picks now tracks 36 programs from $59/month, medication only with a required membership billed beside it (GLP1Picks, read September 20, 2026). The defensible claim is narrower: at $249/month, DirectMeds is the cheapest all-inclusive sublingual semaglutide program with no membership fee (DirectMeds landing page).

Price transparency means showing the long-term bill. At $249–$297/month, a year of the DirectMeds program runs roughly $3,000–$3,600 (DirectMeds landing page) — and GLP-1 treatment is typically ongoing. Long-term data shows much of the lost weight returns after stopping, with about two-thirds regained per the STEP 1 evidence (SeekPeptides). Budget for the treatment horizon, not just month one. If you are weighing a stop, see what happens after you stop.

The Fifth Circuit Ruling: What It Means for Compounded GLP-1 Prices

On August 27, 2026, a Fifth Circuit panel affirmed the FDA in both compounding appeals: OFA v. FDA, No. 25-10758 (semaglutide) and No. 25-10600 (tirzepatide) (opinion 25-10758, opinion 25-10600). With the shortage exemptions gone, mass compounding of “essentially copies” of semaglutide and tirzepatide is no longer permitted: 503A pharmacies must stop immediately, while 503B outsourcing facilities get a 60-day wind-down (LegalClarity). The only remaining path is a patient-specific formulation with a documented clinical difference — and price alone does not qualify (LegalClarity). We broke it down in full in our compounded GLP-1 ruling explainer.

The ruling caps a shift that began when the FDA declared the semaglutide shortage over on February 21, 2025 — what Fierce Healthcare called “a big loss for some telehealth companies” (Fierce Healthcare, Feb 21, 2025). It is already visible in today’s pricing: the biggest platforms — Hims, Ro, Noom, WeightWatchers, LifeMD — now sell FDA-approved brands with membership fees layered on top, while low-cost compounded offers survive mainly at Mochi and Found, whose legal footing the ruling narrowed (Hims, Mochi, Found). Supply is tightening just as the FDA weighs an April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (LegalClarity) — fewer legal compounders can mean higher prices or pulled offers, the same regulatory squeeze behind Novo and Lilly’s push to end compounded GLP-1s.

Oral GLP-1s Are Reshaping the Price Floor

The cheapest brand-name cash price in the market right now is a pill. The Wegovy pill runs $149–$199/month via NovoCare, and Lilly’s Foundayo — oral orforglipron, the first FDA-approved oral GLP-1 from Lilly, approved April 2026 — sells at $149–$349/month (GLP-1 Daily, RX Index, Mochi). Mochi describes the Wegovy pill as “the first FDA-approved GLP-1 pill for chronic weight management,” and it now sits on telehealth storefronts like Hims alongside the injectables (Mochi, Hims). Our oral GLP-1 comparison covers every pill in or near the clinic.

More orals are coming. In a phase 2b trial in Nature Medicine, the experimental oral aleniglipron produced average weight losses of 9.0% at 45 mg, 10.7% at 90 mg, and 12.1% at 120 mg over 36 weeks — versus 0.5% placebo — in 230 adults at 38 U.S. centers, with phase III planned (ScienceDaily / Northwestern Medicine, Aug 10, 2026). We covered the aleniglipron phase 2b results when they landed. The pricing pressure is showing on branded orals too: in February 2026, Hims & Hers announced a $49/month oral semaglutide lookalike — the FDA objected and Novo Nordisk sued for patent infringement (Motley Fool, Feb 9, 2026). The same pressure keeps DirectMeds’ $249/month tier competitive (GlobeNewswire, Aug 28, 2026).

How to Choose the Cheapest GLP-1 for Your Situation

• Insured and GLP-1s covered: use a manufacturer savings card — most people pay $25 or less per month (GLP-1 Daily).
• On Medicare: check the Medicare GLP-1 Bridge — eligible Part D members can get Wegovy, Zepbound, or Foundayo for about $50/month through December 31, 2027 (Found, GLP-1 Daily).
• Paying cash: compare manufacturer direct programs ($149–$499) against telehealth all-in plans ($99–$397) and compounded options — and remember compounded supply is now legally constrained after the Fifth Circuit ruling (RX Index, GLP-1 US, LegalClarity).
• For compounded semaglutide specifically: verify the pharmacy is 503A-licensed, check the concentration, and look for LegitScript certification before buying (DirectMeds landing page, SeekPeptides) — run our compounding pharmacy checklist first.

Whatever tier you pick, treat “starting at” prices as the floor, add membership plus medication for the real monthly total, and confirm the regulatory footing — mass compounding of essentially copies is no longer legal, so the cheapest offer is worth little if the pharmacy can’t legally fill it (LegalClarity).

FAQ

How much does GLP-1 cost in 2026?

From $0 to more than $1,349/month, depending on insurance and channel (GLP-1 Daily). With insurance plus a manufacturer savings card, many people pay $25 or less; eligible Medicare Part D members pay about $50/month through the GLP-1 Bridge; cash-pay manufacturer programs run $149–$499; and compounded telehealth plans run roughly $99–$397 (GLP-1 Daily, RX Index, GLP-1 US, Found).

What is the cheapest GLP-1 online?

Compounded semaglutide is the low-cost tier: GLP1Picks tracks 36 programs starting at $59/month, medication only with a required membership billed beside it, and injectable bundles run about $99/month at the low end (GLP1Picks, read September 20, 2026). The cheapest all-inclusive sublingual program is DirectMeds at $249/month with no membership fee (DirectMeds landing page), and the cheapest brand-name cash path is the Wegovy pill at about $149/month (GLP-1 Daily).

Is $249/month a good price for semaglutide?

Yes for what it bundles — roughly 76–82% below brand-name list prices of ~$1,028–$1,349/month, with medication, doctor visits, shipping, and supplies in one price and no membership fee (RX Index). It is not the absolute floor: injectable compounded bundles start around $99/month (GLP1Picks), so $249 is best framed as the cheapest all-inclusive sublingual option (DirectMeds landing page).

What does DirectMeds’ $249/month plan include?

Sublingual semaglutide, doctor visits (normally $99/visit), 2-day FedEx shipping, and supplies — plus ongoing clinical support and provider oversight (DirectMeds landing page). There are no separate membership or access fees, and payments are HSA/FSA-eligible (DirectMeds landing page, GlobeNewswire, Aug 28, 2026). “Starting at” pricing applies, and medication is prescribed only when clinically appropriate.

Are compounded GLP-1s still legal after the Fifth Circuit ruling?

Mass compounding of essentially copies of semaglutide and tirzepatide is no longer permitted: 503A pharmacies must stop immediately, 503B facilities get a 60-day wind-down (LegalClarity). The remaining path is patient-specific formulation with a documented clinical difference — price alone doesn’t qualify (opinion 25-10758, opinion 25-10600).

How much does semaglutide cost per month with or without insurance?

With insurance plus a savings card, semaglutide can cost as little as $25/month (GLP-1 Daily). Without insurance, costs run roughly $149–$1,349/month: manufacturer cash programs from about $149, telehealth all-in plans about $99–$397, brand-name list prices up to ~$1,349 (GLP-1 Daily, GLP-1 US).

Why won’t my employer cover GLP-1?

Many employers still don’t cover weight-loss GLP-1s — only 36% cover them for both diabetes and weight loss, 60% cover them for diabetes only, and 3% don’t cover them at all (IFEBP survey, June 2026) (Becker’s Payer Issues, Jul 7, 2026). The drugs have become one of the fastest-growing costs in employer health plans, and covering them significantly increased prescription drug costs, which has led some employers — including Cigna and PepsiCo — to scale back or drop weight-loss coverage. ABC News reported on August 29, 2026 that patients who lose coverage can face more than $1,000 per month out of pocket (ABC News, Aug 29, 2026).

Does Medicare cover Wegovy or Zepbound?

Regular Medicare Part D does not cover GLP-1s used only for weight loss, but the Medicare GLP-1 Bridge changes that for eligible beneficiaries through December 31, 2027: qualifying Part D members can get Wegovy (injection or tablet), Zepbound (KwikPen only), or Foundayo for about $50/month (CMS). Zepbound’s single-dose pen and vials are not covered. See our Medicare GLP-1 Bridge explainer for the full eligibility rules and how enrollment works.

This article is for informational purposes only and is not medical advice. Prices are “starting at” figures observed on the dates stated in the table, and can change at any time.